Full-Time

Head of Formulation and Drug Product Development

Confirmed live in the last 24 hours

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Biotechnology firm specializing in antibody therapies

Biotechnology
Healthcare

Compensation Overview

CA$152.9k - CA$229.3kAnnually

+ Equity + Annual Bonus

Senior, Expert

Vancouver, BC, Canada

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • 12-15+ years of industry experience with a PhD in a relevant scientific discipline. Strong candidates with BSc or MSc degrees may be considered with sufficient Process Development and leadership experience
  • 6+ years of experience building, leading, and developing a cross-functional team
  • Experience in establishing and running a Formulation Development team for monoclonal antibodies and other protein biologics
  • Experience establishing phase-appropriate first-in-human formulation development strategies, including stability evaluation, biophysical characterization, and clinical in-use evaluation
  • Experience overseeing the execution of formulation and drug product development activities at CDMO partner sites
  • Experience in working closely with Quality teams to establish workflows that enable successful documentation, data capture, and data integrity, ensuring compliance with industry standards
  • Deep knowledge of global regulatory expectations for the development of protein biologics, including experience supporting INDs, CTAs, and other regulatory filings. Direct experience interacting with regulatory agencies and health authorities is desired
  • Bias towards innovation over industry standards, keen to do things differently, and passionate about building dynamic teams and capabilities that accomplish important goals
  • Strongly self-motivated and able to identify project needs and follow that up with building and implementing solutions
  • Experience with device development and/or antibody-drug conjugates
Responsibilities
  • Further developing the overall strategy for all aspects of formulation, drug product, and clinical in-use development for therapeutic antibodies
  • Developing the formulation and drug product team and workflows to deliver appropriate formulations and drug products for AbCellera’s pipeline
  • Supporting and providing strategic guidance to meet near and long term clinical demands with a network of CMOs and CDMOs, as needed
  • Providing a beginning-to-end solution for all aspects of antibody formulation development
  • Working closely with AbCellerites to develop an innovative approach to CMC development that is closely integrated with our antibody discovery and development workflows
  • Developing workflows for screening and selecting lead antibody molecules with optimal developability and manufacturing properties
  • Preparing regulatory documents and communicating with health authorities
  • Continuously driving improvements to the established processes, increasing speed and efficiency while meeting regulatory requirements

AbCellera specializes in discovering and developing therapeutic antibodies for various diseases. The company uses a proprietary technology platform that combines different scientific methods to identify and create antibodies efficiently. Clients, including pharmaceutical companies and research institutions, partner with AbCellera to enhance their drug development processes. Unlike many competitors, AbCellera focuses on challenging targets that traditional methods struggle to address. The company aims to accelerate the development of new medicines through collaborations, generating revenue from discovery services, licensing agreements, and its own therapeutic programs.

Company Stage

Grant

Total Funding

$620.9M

Headquarters

Vancouver, Canada

Founded

2012

Growth & Insights
Headcount

6 month growth

5%

1 year growth

0%

2 year growth

33%
Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic collaborations with firms like Viking Global Investors and Biogen expand AbCellera's capabilities and market opportunities.
  • AbCellera's participation in high-profile industry conferences and presentations, such as AACR, showcases its cutting-edge research and strengthens its industry reputation.
  • The company's internal pipeline of therapeutic programs offers potential for significant breakthroughs and new treatments.

What critics are saying

  • The highly competitive and rapidly evolving biopharmaceutical market requires continuous innovation to maintain a competitive edge.
  • The recent resignation of board member Peter Thiel could lead to strategic and governance challenges.

What makes AbCellera Biologics unique

  • AbCellera's proprietary technology platform accelerates antibody discovery, making it faster and more efficient than traditional methods.
  • The company's ability to tackle challenging targets that have been difficult to address with traditional methods sets it apart in the biopharmaceutical market.
  • AbCellera's collaborative business model, which includes partnerships with leading investment firms and biotech companies, enhances its innovation and market reach.

Help us improve and share your feedback! Did you find this helpful?